Piper Sandler Initiates Coverage of Benitec Biopharma (BNTC) with Overweight Recommendation
NASDAQ · 3d ago
Piper Sandler starts Benitec at overweight, cites BB-301 opportunity
Healthcare Piper Sandler starts Benitec at overweight, cites BB-301 opportunity. The investment bank believes the therapy has a strong probability of success in the treatment of oculopharyngeal muscular dystrophy. Piper has a price target of $30 for the stock.
Seeking Alpha · 3d ago
Benitec Biopharma Price Target Announced at $30.00/Share by Piper Sandler
Dow Jones · 3d ago
Benitec Biopharma Initiated at Overweight by Piper Sandler
Dow Jones · 3d ago
Piper Sandler Initiates Coverage On Benitec Biopharma with Overweight Rating, Announces Price Target of $30
Benzinga · 3d ago
Buy Rating on Benitec Biopharma: Promising Prospects for OPMD Treatment with BB-301
TipRanks · 3d ago
Weekly Report: what happened at BNTC last week (0603-0607)?
Weekly Report · 6d ago
Weekly Report: what happened at BNTC last week (0527-0531)?
Weekly Report · 06/03 11:54
Weekly Report: what happened at BNTC last week (0520-0524)?
Weekly Report · 05/27 12:00
CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements
Seeking Alpha · 05/23 20:47
Weekly Report: what happened at BNTC last week (0513-0517)?
Weekly Report · 05/20 11:51
Buy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid Financials
TipRanks · 05/20 04:25
Benitec Biopharma files to sell 32.87M shares of common stock for holders
Healthcare Benitec Biopharma files to sell shares of common stock for holders May 16, 2024 10:21am ET. Benite c biopharma filed a prospectus related to the proposed resale of million common shares by the selling stockholders.
Seeking Alpha · 05/16 14:21
BNTC Stock Earnings: Benitec Biopharma Misses EPS for Q3 2024
Benitec Biopharma reported earnings per share of -$ for the third quarter of 2024. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -78 cents. Benitec biopharma also reported results for the fourth quarter of 2015.
Investorplace · 05/13 18:53
FFIE, OGEN and CCLD among mid-day movers
On the Move FFIE, OGEN and CCLD among mid-day movers. CareCloud (CCLD) and Gamestop Corporation (GME) Gainers: CareCloud, Novavax and Tupperware Brands Corporation. Losers: TransCode Therapeutics and Koss Corp.
Seeking Alpha · 05/13 17:30
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers CareCloud stock moved upwards by to $ during Monday's regular session. Novavax stock rose   to $ after their, Q1 earnings came out yesterday. The company's market cap stands at $ billion. Losers TransCode Therapeutics and Applied DNA Sciences also declined.
Benzinga · 05/13 16:31
Benitec GAAP EPS of -$1.64
Benitec Biopharma Inc. Reports Q3 GAAP EPS of -$ . The company had $ million in cash and cash equivalents as of March 31. Total revenues for the quarter ended March 31 were $0 compared to $54,000 a year-ago.
Seeking Alpha · 05/13 14:28
Benitec Biopharma Q3 2024 Revenue $0 Down From $54,000 YoY
Benzinga · 05/13 12:19
Benitec Biopharma Q3 2024 GAAP EPS $(1.64) Misses $(0.78) Estimate
Benzinga · 05/13 12:18
Reuters · 05/13 12:15
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc. is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The Company’s platform, DNA-directed RNA interference (ddRNAi), combines ribonucleic acid (RNA) interference with gene therapy to create medicines that facilitate sustained silencing of disease-causing genes following a single administration. The Company is also engaged in developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The Company's BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to permanently silence the expression of the disease-causing gene (to slow, or halt, the biological mechanisms underlying disease progression in OPMD) and to simultaneously replace the mutant gene with a wildtype gene (to drive restoration of function in diseased cells).